Dose-optimized stereotactic body radiotherapy for locally advanced or recurrent pancreatic andenocarcinoma

Dose-optimized stereotactic body radiotherapy for locally advanced or recurrent pancreatic andenocarcinoma - ORP 001

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00027912

Enrollment

Registered

2022-09-09

Start date

2022-09-07

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25

Interventions

Group 1: SBRT of 7 fractions with 6,5 Gy each, chemotherapy according German S3 Guideline for pancreatic cancer

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Locally advanced pancreatic cancer - recurrent pancreatic cancer

Exclusion criteria

Exclusion criteria: -previous Radiotherapy -more advanced stadium than oligometastatic disease -PTV more than 75 ml

Design outcomes

Primary

Measure	Time frame
freedom from local progression (FFLP)	—

Secondary

Measure	Time frame
Quality of life We will conduct the surveys at the following timepoints: At the end of the radiotherapy after 6 weeks after 3 Months further every 3 Months	—

Countries

Germany

Contacts

Public ContactThomas Gryc

Nordstrahl

gryc@nordstrahl.de0911933560

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026